MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517061664 A) filed by Renji Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, on June 27, for 'priority particulars of the application (s) filed in convention country.'
Inventor(s) include Wei, Weijun; Wu, Qianyun; and Liu, Jianjun.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "Provided in the present invention are a preparation method for and the use of a CD70-specific integrated diagnosis and treatment molecular imaging probe. The probe comprises a tumor targeting group and radionuclides. The tumor targeting group is selected from a CD70-specific nanoantibody or a CD70-specific nanoantibody fusion protein, wherein the CD70-specific nanoantibody is B3 or B6, the amino acid sequences thereof being shown as SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70 specific nanoantibody fusion protein is ABDB3 or ABDB6, the amino acid sequences thereof being shown as SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves non-invasive visualization of human CD70 molecular expression and thus achieves noninvasive diagnosis of renal cell carcinoma. The probe has the advantages of simple preparation process, low cost, high specificity, high stability, short imaging period, low radiation dose, easiness in clinical conversion, etc."
The patent application was internationally filed on Nov. 29, 2023, under International application No.PCT/CN2023/134962.
Disclaimer: Curated by HT Syndication.
